In a phase 1 study of pexidartinib, fatigue, diarrhea, anemia, and neutropenia were observed in one case each and hyponatremia and aspartate aminotransferase (AST)/alanine transaminase (ALT) elevation were observed in two cases each (47). This evidence concerns the gene GPT and Decreased total neutrophil count.